Login
$RZLT
$3.53 -$0.05 (1.4%) After hours

$RZLT 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

13 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation

05 Nov 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ...

29 Oct 2026 8-K: Regulation FD Disclosure

A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation

14 Oct 2026 8-K: Regulation FD Disclosure

REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced...

05 Oct 2026 8-K: Regulation FD Disclosure

The Agency reiterated its commitment to addressing the unmet need for treatment

24 Sep 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ...

02 Jun 2026 8-K: Regulation FD Disclosure

6 of 8 participants have already met the responder criterion for the study’s primary endpoint

12 May 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., May 12, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial re...

04 May 2026 8-K: Regulation FD Disclosure

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

24 Mar 2026 8-K: Regulation FD Disclosure

FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program

12 Feb 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., February 12, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financi...

07 Jan 2026 8-K: Regulation FD Disclosure

A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation

21 Nov 2025 8-K: Submission of Matters to a Vote of Security Holders

Rezolute, Inc. (the “Company”) held its 2026 annual meeting of stockholders on November 19, 2025. The meeting was held virtually at www.virtualshareholdermeeting.com/RZLT2025. As of the record date, September 22, 2025, there were a total...

12 Nov 2025 8-K: Regulation FD Disclosure

Rezolute Investor Event: Ersodetug Development Program November 10, 2025

06 Nov 2025 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., November 6, 2025 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and prov...

21 Oct 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
17 Sep 2025 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., September 17, 2025 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and pr...

02 Sep 2025 8-K: Regulation FD Disclosure

A Late - stage Rare Disease Company Treating Hyperinsulinism Corporate Presentation NASDAQ: RZLT

20 Aug 2025 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support